[Asia Economy Reporter Junho Hwang] ST Pharm announced on the 9th that it has signed a supply contract for low-molecular-weight new drug active pharmaceutical ingredients for approval application with a US-based biotech company, worth 9,071,680,000 KRW. The contract amount corresponds to 9.7% of the consolidated sales in 2019. The contract period is until November 30.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

